Yearly tuberculosis re-testing in people with autoimmune rheumatic diseases on immune-lowering treatment
Tests whether yearly tuberculosis re-screening lowers active tuberculosis in people with autoimmune rheumatic diseases.
Plain-language title generated from the registry record
Registry title: Incidence of Tuberculosis in Patients With Autoimmune Rheumatic Diseases
Key facts
- Where
- São Paulo, BrazilSee the site
Where in Brazil
- Rheumatology Division, Faculdade de Medicina da USP, São Paulo, SPSão Paulo, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Sao Paulo General Hospital
- Trial code
- NCT07731672
- Record updated
- 18 August 2026
- Original description
This is a prospective, randomized, controlled study designed to evaluate the effectiveness of annual re-screening for tuberculosis infection (TBI) (previous) in patients with autoimmune rheumatic diseases (ARDs) receiving biologic and/or immunosuppressive therapy.Read full original descriptionShow less
Prospective Randomized Controlled Study to Evaluate the Effectiveness of Annual Tuberculosis Re-Screening in Patients With Autoimmune Rheumatic Diseases Receiving Biologic and/or Immunosuppressive Therapy
This is a prospective, randomized, controlled study designed to evaluate the effectiveness of annual re-screening for tuberculosis infection (TBI) (previous) in patients with autoimmune rheumatic diseases (ARDs) receiving biologic and/or immunosuppressive therapy.
Patients with negative baseline TBI screening will be randomized to undergo annual re-screening using interferon-gamma release assay (IGRA) or to a control group without routine re-screening.
Patients with newly detected TBI will receive preventive treatment. The primary objective is to assess whether annual re-screening combined with TBI treatment reduces the incidence of active tuberculosis. Secondary objectives include determining TBI conversion rates and identifying risk factors for infection.
Inclusion: Patients (adults and children) diagnosed with autoimmune rheumatic diseases according to established international classification criteria; negative baseline screening for tuberculosis infection.
Exclusion: Radiographic evidence suggestive of prior TB; Previous treatment for TBD or TBI; History of tuberculosis infection or disease; Positive baseline TB screening; Follow-up shorter than 12 months.